Posts by: Patricia Inacio, PhD

News

The U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) as a treatment for people with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) — the second most common ... Read more

June 15, 2020June 15, 2020

Cancer Vaccine Plus Adoptive T-cell Therapy Placed on Fast Track

News

TVI-Brain-1, an immunotherapy being developed by TVAX Biomedical, was given fast track designation by the U.S. Food and Drug Administration (FDA) as a potential treatment of glioblastoma multiforme, a deadly form ... Read more

May 12, 2020May 12, 2020

ICT’s CAR T-cell Therapy Shows Promise in Reducing Size of Solid Tumors

News

A potential CAR T-cell therapy by Innovative Cellular Therapeutics (ICT) showed early signs of safety and efficacy, significantly reducing tumor size in four patients with thyroid or colorectal cancer, new ... Read more

February 14, 2020February 14, 2020

Ilixadencel Improves Responses, Extends Survival in Newly-diagnosed Metastatic Kidney Cancer, Trial Results Show

News

Adding Immunicum‘s ilixadencel to standard surgical and medical treatment for newly-diagnosed metastatic renal cell carcinoma — the most common form of kidney cancer — increases patient responses, duration of response, and ... Read more

December 12, 2019January 6, 2020

Gut Bacteria as Means of Boosting Immunotherapy in Advanced Cancers Focus of Clinical Trial

News

Vedanta Bioscience has started a Phase 1/2 trial to test its investigational oral microbiome therapy, VE800, in combination with the immune checkpoint inhibitor Opdivo (nivolumab) as treatment for certain advanced cancers. ... Read more

November 27, 2019November 27, 2019

Surface Oncology Asking to Open Trial of Antibody Therapy for Advanced Solid Cancers

News

Surface Oncology is requesting approval to open a Phase 1/1b clinical trial testing SRF617, an anti-CD39 antibody, either alone or in combination with other cancer immunotherapies in people with advanced solid tumors. ... Read more

October 18, 2019

First Patients Dosed in Phase 1/2 Trial Testing Galinpepimut-S, Keytruda Combo in Advanced Cancers

News

A Phase 1/2 clinical trial assessing the cancer vaccine galinpepimut-S in combination with Keytruda (pembrolizumab) as a treatment for WT-1-positive advanced cancers has started dosing patients, Sellas Life Sciences ... Read more

September 20, 2019September 20, 2019

FDA Fast-tracks Magrolimab for Treatment of Myelodysplastic Syndrome, Acute Myeloid Leukemia

News

Magrolimab, an experimental antibody developed by Forty Seven, was granted fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML) and ... Read more

September 3, 2019

Imfinzi-Tremelimumab Combo Fails to Prolong Overall Survival in Metastatic NSCLC, Phase 3 Trial Shows

News

A combination of tremelimumab plus Imfinzi (durvalumab) is no better than standard chemotherapy at extending the survival of people with metastatic non-small cell lung cancer (NSCLC) with a high ... Read more

August 30, 2019

Pexa-Vec Combo Unlikely to Benefit Advanced Liver Cancer Patients in Phase 3 Trial, Monitoring Group Says

News

Adding the cancer vaccine Pexa-Vec to Nexavar (sorafenib), a standard of care, is not likely to improve overall survival of patients with advanced liver cancer, an interim analysis by the ... Read more

Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

FDA Approves Keytruda for Advanced Squamous Cell Skin Cancer

Cancer Vaccine Plus Adoptive T-cell Therapy Placed on Fast Track

ICT’s CAR T-cell Therapy Shows Promise in Reducing Size of Solid Tumors

Ilixadencel Improves Responses, Extends Survival in Newly-diagnosed Metastatic Kidney Cancer, Trial Results Show

Gut Bacteria as Means of Boosting Immunotherapy in Advanced Cancers Focus of Clinical Trial

Surface Oncology Asking to Open Trial of Antibody Therapy for Advanced Solid Cancers

First Patients Dosed in Phase 1/2 Trial Testing Galinpepimut-S, Keytruda Combo in Advanced Cancers

FDA Fast-tracks Magrolimab for Treatment of Myelodysplastic Syndrome, Acute Myeloid Leukemia

Imfinzi-Tremelimumab Combo Fails to Prolong Overall Survival in Metastatic NSCLC, Phase 3 Trial Shows

Pexa-Vec Combo Unlikely to Benefit Advanced Liver Cancer Patients in Phase 3 Trial, Monitoring Group Says

Pin It on Pinterest